Cyclerion Therapeutics Inc.
13F holders, Q1 2026 (March 31)17holders −2
3new positions
5sold out
1famous investor
$1.54avg. 13F price*
At the end of Q1 2026, 17 institutions reported holding Cyclerion Therapeutics Inc. in their 13F filings, down 2 from Q4 2025. 3 opened new positions and 5 sold out. The largest holders were Geode Capital Management, LLC ($130K), Citadel Advisors ($28K) and BlackRock, Inc. ($26K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Cyclerion Therapeutics Inc.
- CUSIP
- 23255M204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $44K |
| Exits | 5 | $216K |
All 13F filers, Q4 2025 → Q1 2026: 72,528 shares bought and 178,561 shares sold, net −106,033 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Geode Capital Management, LLC | 0.00% | Add +95.3% | 84,550 | $130K |
| Citadel Advisors | 0.00% | New | 18,261 | $28K |
| BlackRock, Inc. | 0.00% | No change | 16,797 | $26K |
| Vanguard Capital Management LLC | 0.00% | — | 16,137 | $25K |
| Kovack Advisors, Inc. | 0.00% | New | 10,000 | $16K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 7,353 | $11K |
| FMR LLC | 0.00% | No change | 4,740 | $7K |
| UBS Group AG | 0.00% | Add +801.9% | 3,391 | $5K |
| Group One Trading LLC | 0.00% | No change | 192 | $295 |
| Osaic Holdings, Inc. | 0.00% | No change | 130 | $201 |
| MAI Capital Management | 0.00% | No change | 100 | $155 |
| Activest Wealth Management | 0.00% | No change | 100 | $155 |
| Citigroup Inc. | 0.00% | Reduce -98.9% | 89 | $137 |
| WHI TRUST Co LLC | 0.00% | No change | 72 | $112 |
| BNP Paribas Financial Markets | 0.00% | No change | 5 | $8 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 4 | $6 |
| Morgan Stanley | 0.00% | No change | 1 | $2 |
"% of holder's portfolio" is CYCLERION THERAPEUTICS INC's weight in each manager's 13F, not the share of Cyclerion Therapeutics Inc. the manager owns.